The sensitivity and specificity of the caffeine-halothane contracture test

Anesthesiology

Volumn 88, Issue 3, 1998, Pages 579-588

  Allen, Gregory C ^a   Larach, Marilyn Green ^b   Kunselman, Allen R ^b  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b NONE

Author keywords

Epidemiology; Measurement techniques; Skeletal muscle; Susceptibility

Indexed keywords

CAFFEINE; HALOTHANE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; HUMAN; HUMAN TISSUE; MALE; MALIGNANT HYPERTHERMIA; MOLECULAR GENETICS; MUSCLE BIOPSY; MUSCLE CONTRACTURE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC;

ADULT; CAFFEINE; CONTRACTURE; FEMALE; HALOTHANE; HUMANS; MALE; MALIGNANT HYPERTHERMIA; MIDDLE AGED; MUSCLES; REGISTRIES;

EID: 0031951496     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-199803000-00006     Document Type: Article

References (23)

1. The European Malignant Hyperpyrexia Group: A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 1984; 56:1267-9
2. Larach MG, for the North American Malignant Hyperthermia Group: Standardization of the caffeine halothane muscle contracture test. Anesth Analg 1989; 69:511-5
3. Larach MG, Landis JR, Bunn JS, Diaz M, The North American MH Registry: Prediction of malignant hyperthermia susceptibility in low-risk subjects. ANESTHESIOLOGY 1992; 76:16-27
4. Larach MG, Localio AR, Allen GC, Denborough MA, Ellis FR, Gronert GA, Kaplan RF, Muldoon SM, Nelson TE, Ørding H, Rosenberg H, Wand BE, Wedel DJ: A clinical grading scale to predict malignant hyperthermia susceptibility. ANESTHESIOLOGY 1994; 80:771-9
5. Kuritz SJ, Landis JR, Koch GG: A general overview of Mantel-Haenszel methods: Applications and recent developments. Ann Rev Public Health 1988; 9:123-60
6. Hosmer DW, Lemeshow S: Applied Logistic Regression. New York, John Wiley & Sons, 1989
7. Hanley JA, McNeil BJ: A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148:839-43
8. Youden WJ: Index for rating diagnostic tests. Cancer 1950; 3:32-5
9. Leisenring W, Sullivan Pepe M, Longton G: A marginal regression modelling framework for evaluating medical diagnostic tests. Stat Med 1997; 16:1263-81
10. Larach MG, Fuhrmann LJ, Allen GC: The epidemiology of malignant hyperthermia events in North America, Malignant Hyperthermia - Proceedings of the 3rd International Symposium on Malignant Hyperthermia, 1994. Edited by M Morio, H Kikuchi, O Yuge. New York, Springer, 1996, pp 39-42
11. Allen GC, Fletchcr JE, Huggins FJ, Conti PA, Rosenberg H: Caffeine and halothane contracture testing in swine using the recommendations of the North American Malignant Hyperthermia Group. ANESTHESIOLOGY 1990; 72:71-6
12. Fletchcr JE, Calvo PA, Rosenberg H: Phenotypcs associated with malignant hyperthermia susceptibility in swine genotyped as homozygous or heterozygous for the ryanodine receptor mutation. Br J Anaesth 1993; 71:410-7
13. Ørding H for the European Malignant Hypothermia Group: In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: Results of testing patients surviving fulminant MH and unrelated low-risk subjects. Acta Anaesthesiol Scand 1997; 41:955-66
14. Ørding H, Bendixen D: Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia. Eur J Anaesth 1992; 9:367-76
15. Isaacs H, Badenhorst M: False-negative results with muscle caffeine halothane contracture testing for malignant hypothermia. ANESTHESIOLOGY 1993; 79:5-9
16. Johnson HA: Diminishing returns on the road to diagnostic certainty. JAMA 1991; 265:2229-31
17. Serfas KD, Bose D, Patel L, Wrogemann K, Phillips MS, MacLennan DH, Greenberg CR: Comparison of the segregation of the RYR C1840T mutation with segregation of the caffeine/hnlothane contracture test results for malignant hypothermia susceptibility in a large Manitoba Mennonite family. ANESTHESIOLOGY 1996; 84:322-9
18. Allen GC: Malignant hyperthermia: Recognition and management of susceptible patients. Curr Opin Anesthesiol 1996; 9:271-5
19. Wallace AJ, Wooldridge W, Kingston HM, Harrison MJ, Ellis FR, Ford PM: Malignant hypothermia - A large kindred linked to the RYR1 gene. Anaesthesia 1996; 51:16-23
20. MacKenzie AE, Allen G, Lahey D, Crossan M-L, Nolan K, Mettler G, Worten RG, MacLennan DH, Korneluk R: A comparison of the caffeine halothane muscle contracture test with the molecular genetic diagnosis of malignant hyperthomia. ANESTHESIOLOGY 1991; 75:4-8
21. Fletcher RH, Fletcher SW, Wagner EH: Clinical Epidemiology: The Essentials, 3rd ed. Baltimore, Williams and Wilkins, 1996, pp 54-6
22. Larach MG: Should we use muscle biopsy to diagnose malignant hypothermia susceptibility? ANESTHESIOLOGY 1993; 79:1-4
23. Bachand M, Vachon N, Boisvert M, Mayer FM, Chartrand D: Clinical reassessment of malignant hyperthermia in Abitibi - Temiscamingue. Can J Anaesth 1997; 44:696-701